CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 81 enrolled
Drug / intervention
OSI-774: erlotinib, TarcevaTMdrug
Likely dose
OSI-774: erlotinib, TarcevaTM 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00590902
NCT00590902Phase 2Completed
CompareCT.gov

Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) In Patients With Advanced Bronchioloalveolar Cell Lung Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 11, 2008·Updated Oct 16, 2023

In Brief

A Phase 2 clinical trial evaluating OSI-774: erlotinib, TarcevaTM for Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer. Completed, enrolled 81 participants across 1 site.

Detailed Summary

The primary objective of this study is to determine the major objective response rate of OSI-774 in participants with unresectable or metastatic bronchioloalveolar cell variant of non-small cell lung cancer. This study is a Phase II study. The first study of OSI-774 was done to evaluate what dose should be given to patients with cancer has been completed. The purpose of this research study is to see whether this experimental treatment, called OSI-774, can cause a type of non-small cell lung cancer to stop growing or shrink. This study is sponsored by a company called Genentech, and is being done at Memorial Hospital, as well as other cancer centers around the country interested in developing new drugs for the treatment of this type of cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchioloalveolar Cell Variant of Non-small Cell Lung Cancer
CountriesUnited States
CollaboratorsM.D. Anderson Cancer Center, Northwestern University, Vanderbilt-Ingram Cancer Center, Dana-Farber Cancer Institute, Genentech, Inc.

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 11, 2008
Enrollment StartMar 1, 2002
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10.9 yearsPosted 18.5 years ago

Interventions

OSI-774: erlotinib, TarcevaTMdrug

150 mg, 100 mg and 25 mg tablets